Building New Bonds in Biomaterials

How do we prevent the body from rejecting long-term implants like artificial hips? The key is designing and utilizing the right materials.

 |  Transcript [PDF]

In medicine, many devices, implants, and diagnostic tools need to be in long-term contact with a patient’s body. When materials have to interact with biology, there are many characteristics that need to be considered to make sure they behave as they should.

Modern biomaterials science looks not only at how cells and proteins interact with traditional materials, but also at how molecular design of new materials can control those interactions. Paul Santerre, professor of biomaterials and biomedical engineering at the University of Toronto, designs polymers for tissue engineering and drug delivery.

“Polyethylene is one of the most successful biomaterials that’s used in artificial hips,” explains Santerre. “It’s the cup component that the metal stem comes up on and rotates around. Anybody who knows somebody with an artificial hip will know the dramatic difference that that has made in people’s lives.”

Polymers are chains of repeating building blocks, and their length and composition can be tuned to give different properties. For instance, shorter chains may only have two or three points of interaction with each other, making them easy to break apart. By contrast, longer chains can have hundreds or thousands of interactions with their neighbours, helping them stay together.

Depending on the application, chain length is just one property that can be manipulated to give different characteristics. Some biomaterials might be designed to be easily degraded, like dissolvable stitches. Others might need to withstand high pressure or shear forces without wearing away.

“We design plastics that are made up of more than one type of building block,” says Santerre. “They’re made up of three or four different types of building blocks. And if you distribute those properly, you can minimize the denaturation (unfolding) of the proteins that are the first signals to immunity.”

Minimizing the immune response to a biomaterial is key to avoiding complications, ensuring that inflammation doesn’t trigger rejection of an implant.

“We have a new polymer platform and we’re driving all kinds of applications with those materials,” adds Santerre. “We’re engineering brand new vessels. We’re engineering spinal discs, periodontal tissues. And that’s pretty cool, that’s pretty hot in recent stuff.”

Santerre is also passionate about bringing science to the market, commercializing his own innovations through his start-up Interface Biologics. As co-founder of the Health Innovation Hub at the University of Toronto, a co-curricular training program for student entrepreneurs, he has helped over 120 health science start-ups get off the ground.

From designing materials to engineering opportunities, these strides are making their mark on healthcare.

‹ Previous post
Next post ›

J. Paul Santerre has published over 180 peer reviewed publications and is a listed inventor on over 60 patents in the area of medical polymers, biodegradation, protein and blood interactions with surfaces, surface modification, regenerative medicine, and drug delivery. His research has led to the training of over 70 graduate students, multiple postdoctoral fellows and over 130 undergraduates, and more than $50M Cdn in grant funding.

In addition to being a named fellow of many national and international academic bodies, he was the past associate Dean research in the Faculty of Dentistry, and past director for the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. He is co-founder and current co-director of the Health Innovation Hub at the University of Toronto (a student focused entrepreneur training co-curricular program with over 120 client health science and biomedical engineering start-up companies to date).

Santerre is a co-founder of Interface Biologics and current CSO for the company. He has received several awards for his innovation and industry related activity including the Governor General’s award for Innovation and the Professional Engineers of Ontario Entrepreneurship Award in 2017. He has recently been awarded with the new Baxter Chair for Health Technology & Commercialization.

He was president of the 2016 World Biomaterials Congress held in Montreal, and has received multiple awards for his community activity including the 2016 Community award from the Canadian Biomaterials, the 2018 President’s Impact Award from the University of Toronto, and the 2018 US Society for Biomaterials Clemson Award for contributions to the literature.

Research2Reality is a groundbreaking initiative that shines a spotlight on world-class scientists engaged in innovative and leading edge research in Canada. Our video series is continually updated to celebrate the success of researchers who are establishing the new frontiers of science and to share the impact of their discoveries with the public.